Chemical function based pharmacophore generation of endothelin-A selective receptor antagonists

Journal of Medicinal Chemistry

Volumn 47, Issue 11, 2004, Pages 2750-2760

  Funk, Oliver F ^a   Kettmann, Viktor ^b   Drimal, Jan ^c   Langer, Thierry ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b Physics and Informatics   (Slovakia)

^c INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR;

ARTICLE; CATALYST; CHEMICAL STRUCTURE; COMPUTER PROGRAM; DRUG SELECTIVITY; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR MODEL; PHARMACOPHORE;

ALGORITHMS; ANIMALS; BINDING, COMPETITIVE; CERCOPITHECUS AETHIOPS; DATABASES, FACTUAL; HETEROCYCLIC COMPOUNDS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RADIOLIGAND ASSAY; RECEPTOR, ENDOTHELIN A; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VERO CELLS;

EID: 2442709037     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm031041j     Document Type: Article

References (66)

1. Inoue, A.; Yanagisawa, M.; Kimura, S.; Kasuya, Y.; Miyauchi, T.; et al. The Human Endothelin Family: Three Structurally and Pharmacologically Dinstinct Isopeptides Predicted by Three Separate Genes. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 2863-2867.
2. Sakurai, T. Y.; Yanagisawa, M.; Masaki, T. Molecular Characterization of Endothelin Receptors. Trends Pharmacol. Sci. 1992, 13, 103-108.
3. Saeki, T.; Ihara, M.; Fukuroda, T.; Yamagiwa, M.; Yano, M. [Ala1,3,11,15]endothelin-1 Analogs with ET-B Agonistic Activity. Biochem. Biophys. Res. Commun. 1991, 179, 286-292.
4. Arai, H.; Hori, S.; Aramori, I.; Ohkubo, H.; Nakanishi, S. Cloning and Expression of a cDNA Encoding an Endothelin Receptor. Nature 1990, 348, 730-732.
5. Panek, R. L.; Major, T. C.; Hingorani, G. P.; Dunbar, J. B.; Doherty, A. M.; et al. Importance of Secondary Structure for Endothelin Binding and Functional Activity. Biochem. Biophys. Res. Commun. 1992, 183, 572-576.
6. Ohlstein, E. H.; Arleth, A.; Bruyan, H.; Elliott, J. D.; Sung, C. P. The Selective Endothelin ETA Receptor Antagonist BQ123 Antagonizes Endothelin-1-Mediated Mitogenesis. Eur. J. Pharmacol. 1992, 225, 347-350.
7. Takayanagi, R.; Kitazumi, R.; Takasaki, C.; Ohnaka, K.; Aimoto, S.; et al. Presence of Non-Selective Type of Endothelin Receptor on Vascular Endothelium and Its Linkage to Vasodilation. FEBS Lett. 1991, 282, 103-106.
8. Warner, T.; Mitchell, J.; De Nucci, G.; Vane, J. Endothelin-1 and Endothelin-3 Release EDRF from Isolated Perfused Arterial Vessels of the Rat and Rabbit. J. Cardiovasc. Pharmacol. 1989, 13, 85-88.
9. De Nucci, G.; Thomas, R.; D'Orleans-Juste, P.; Antunes, E.; Walder, C.; et al. Pressor Effects of Circulating Endothelin Are Limited by the Release of Prostacyclin and Endothelium-Derived Relaxing Factor. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 9797-9800.
10. Kiowski, W.; Sütsch, G.; Hunziker, P.; Muller, P.; Kim, J.; et al. Evidence for Endothelin-1-Mediated Vasoconstriction in Severe Chronic Heart Failure. Lancet 1995, 346, 732-736.
11. Ishikawa, K.; Ihara, M.; Noguchi, K.; Mase, T.; Mino, N.; et al. Biochemical and Pharmacological Profile of a Potent and Selective Endothelin B-Receptor Antagonist, BQ-788. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4892-4896.
12. Stewart, D. J.; Levy, R. D.; Cernacek, P.; Langleben, D. C. Increased Plasma Endothelin-1 in Pulmonary Hypertension: Marker or Mediator of Disease? Ann. Intern. Med. 1991, 114, 464-469.
13. Krum, H.; Viskoper, R. J.; Lacourciere, Y.; Budde, M.; Charlon, V. The Effect of an Endothelin-Receptor Antagonist, Bosentan, on Blood Pressure in Patients with Essential Hypertension. N. Engl. J. Med. 1998, 338, 784-790.
14. Cardillo, C.; Kilcoyne, C. M.; Waclawiw, M.; Cannon, R. O.; Panza, J. A. Role of Endothelin in the Increased Vascular Tone of Patients with Essential Hypertension. Hypertension 1999, 33, 753-758.
15. Moreland, S.; McMullen, D.; Delaney, C.; Lee, V.; Hunt, J. Venous Smooth Muscle Contains Vasoconstrictor ETB-like Receptors. Biochem. Biophys. Res. Commun. 1992, 184, 100-106.
16. Stewart, D. Update on Endothelin. Can. J. Cardiol. 1998, Suppl. D, 11D-13D.
17. Zolk, O.; Quattek, M. S.; Sitzler, G.; Schrader, T.; Nickenig, T.; et al. Expression of Endothelin-1, Endothelin-Converting-Enzyme and Endothelin Receptors in Chronic Heart failure. Circulation 1999, 99, 2118-2123.
18. Wu, C. Recent Discovery and Development of Endothelin Receptor Antagonists. Expert Opin. Ther. Pat. 2000, 10, 1653-1668.
19. Elliot, J. D.; Xiang, J. Endothelin Receptor Antagonists. In Endothelin and Its Inhibitors; Springer: Berlin, 2001; Chapter 9.
20. Sutsch, G.; Kiowski, W.; Yan, X. W. Short-Term Oral Endothelin-Receptor Antagonist Therapy in Conventionally Treated Patients with Symptomatic Severe Chronic Heart Failure. Circulation 1998, 98, 2262-2268.
21. Kalra, P. R.; Moon, J. C.; Coats, A. J. Do Results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) Study Spell the End for Non-Selective Endothelin Antagonism in Heart Failure? Int. J. Cardiol. 2002, 85, 195-197.
22. Maloney, J. P. Advances in the treatment of secondary pulmonary hypertension. Curr. Opin. Pulm. Med. 2003, 9, 139-143.
23. Verhaar, M. C.; Strachan, F. E.; Newby, D. E.; Cruden, N. L.; Koomans, H. A.; et al. Endothelin-A Receptor Antagonist Mediated Vasodilatation is Attenuated by Inhibition of Nitric Oxide Synthesis and by Endothelin-B Receptor Blockade. Circulation 1998, 97, 752-756.
24. Ohnishi, M.; Wada, A.; Tsutamoto, T.; Fukai, D.; Kinoshita, M. Comparison of the Acute Effets of a Selective Endothelin ET-A and a Mixed ET-A/ET-B Receptor Antagonist in Heart Failure. Cardiovasc. Res. 1998, 39, 617-624.
25. Catalyst, version 4.7; Accelrys Inc., 9685 Scranton Road, San Diego, CA 92121.
26. Li, H.; Sutter, J.; Hoffmann, R. HypoGen: An Automated System for Generating 3D Predictive Pharmacophore Models. In Pharmacophore Perception, Development and Use in Drug Design; International University Line: La Jolla, CA, 2000.
27. Omoshile, O.; Trope Mehl, C.; Trope Mehl, A. HipHop: Pharmacophores Based on Multiple Common-Feature Alignments. In Pharmacophore Perception, Development and Use in Drug Design; International University Line: La Jolla, CA, 2000.
28. Barnum, D.; Greene, J.; Smellie, A.; Sprague, P. Identification of Common Functional Configurations among Molecules. J. Chem. Inf. Comput. Sci. 1996, 36, 563-571.
29. English philosopher and Franciscan monk William of Ockham, 1285-1349.
30. Krovat, E. M.; Langer, T. Non-Peptide Angiotensin II Receptor Antagonists: Chemical Feature Based Pharmacophore Identification. J. Med. Chem. 2003, 46, 716-726.
31. Debnath, A. K. Pharmacophore Mapping of a Series of 2,4-Diamino-5-deazapteridine Inhibitors of Mycobacterium Avium Complex Dihydrofolate Reductase. J. Med. Chem. 2002, 45, 41-53.
32. Karki, R. G.; Kulkarni, M. V. A Feature Based Pharmacophore for Candida Albicans MyristoylCoA: Protein N-Myristoyltransferase Inhibitors. Eur. J. Med. Chem. 2001, 36, 147-163.
33. Kaminski, J. J.; Rane, D. F.; Snow, M. E.; Weber, L.; Rothofsky, M. L.; et al. Identification of Novel Farnesyl Protein Transferase Inhibitors Using Three-Dimensional Database Searching Methods. J. Med. Chem. 1997, 40, 4103-4112.
34. Hirashima, A.; Pan, C.; Kuwano, E.; Taniguchi, E.; Eto, M. Three-Dimensional Pharmacophore Hypotheses for the Locust Neuronal Octopamine Receptor (OAR3). Part 2: Agonists. Bioorg. Med. Chem. 1999, 7, 1437-1443.
35. Langer, T.; Hoffmann, R. D.; Daxenbichler, G.; Bachmair, F.; Begle, S. Chemical Function Based Pharmacophore Models as Suitable Filters for Virtual 3D-Database Screening. J. Mol. Struct.: THEOCHEM 2000, 503, 59-72.
36. Lopez-Rodriguez, M.; Porras, E.; Benhamu, B.; Ramos, J. A.; morcillo, M. J.; et al. First Pharmacophoric Hypothesis for 5-HT7 Antagonism. Bioorg. Med. Chem. Lett. 2000, 10, 1097-1100.
37. Singh, J.; van Vlijmen, J.; Liao, Y.; Lee, W.; Cornebise, M.; et al. Identification of Potent and Novel α4β1 Antagonists Using in Silico Screening. J. Med. Chem. 2002, 45, 2988-2993.
38. Palomer, A.; Cabre, F.; Pascual, J.; Campos, J.; Trujillo, M. A.; et al. Identification of Novel Cyclooxygenase-2 Selective Inhibitors Using Pharmacophore Models. J. Med. Chem. 2002, 45, 1402-1411.
39. Kurogi, Y.; Miyata, K.; Okamura, T.; Hashimoto, K.; Tsutsumi, K.; et al. Discovery of Novel Mesangial Cell Proliferation Inhibitors Using a Three-Dimensional Database Searching Method. J. Med. Chem. 2001, 44, 2304-2307.
40. Drimal, J.; Bauerova, K.; Kettmann, V.; Knezl, V. C. Counteractive Adrenergic and Endothelin ETB-Receptor Subtype Signaling Modulate Proliferation in Monkey Renal Cells. Biology 2000, 55, 299-304.
41. Saavedra, J. InPlot. A Nonlinear Least-Squares Curve-Fitting Program, version 4.03; GraphPad Software Inc.: New York, 1992.
42. Ishizuka, N.; Matsumara, K.; Sakai, K.; Fujimoto, M.; Mihara, S.; et al. Structure-Activity Relationships of a Novel Class of Endothelin-A Receptor Antagonists and Discovery of Potent and Selective Receptor Antagonist, 2-(Benzo[1,3]dioxol-5-yl)-6-isopropyloxy-4-(4-methoxyphenyl) -2H-chromene-3-carboxylic Acid (S-1255). 1. Study on Structure-Activity Relationships and Basic Structure Crucial for ETA Antagonism. J. Med. Chem. 2002, 45, 2041-2055.
43. Jae, H.; Winn, M.; Dixon, D. B.; Marsh, K. C.; Nguyen, B.; et al. Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 2. Sulfonamide-Based ETA/ETB Mixed Antagonists. J. Med. Chem. 1997, 40, 3217-3227.
44. Liu, G.; Kozmina, N. S.; Winn, M.; von Geldern, T. W.; Chiou, W. J.; et al. Design, Synthesis, and Activity of a Series of Pyrrolidine-3-caboxylic Acid-Based, Highly Specific, Orally Active ETB Antagonists Containing a Diphenylmethylamine Acetamide Side Chain. J. Med. Chem. 1999, 42, 3679-3689.
45. Winn, M.; von Geldern, T. W.; Opgenorth, T. J.; Jae, H.; Tasker, A. S.; et al. 2,4-Diarylpyrrolidine-3-carboxylic Acids-Potent ETA Selective Endothelin Receptor Antagonists. 1. Discovery of A-127722. J. Med. Chem. 1996, 39, 1039-1048.
46. Brooks, B. R.; Brucolleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; et al. CHARMM: A Program for Macromolecular Energy Minimization, and Dynamic Calculations. J. Comput. Chem. 1983, 4, 187-217.
47. Smellie, A.; Teig, S. L.; Towbin, P. Poling: Promoting Conformational Coverage. J. Comput. Chem. 1995, 16, 171-187.
48. Fischer, R. The Principle of Experimentation, Illustrated by a Psycho-Physical Experiment. The Design of Experiments, 8th ed.; Hafner Publishing Co.: New York, 1966; Chapter II.
49. von Geldern, T. W.; Tasker, A. S.; Sorensen, B. K.; Winn, M.; Szczepankiewicz, B. G.; et al. Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 4. Side Chain Conformational Restriction Leads to ET-B Selectivity. J. Med. Chem. 1999, 42, 3668-3678.
50. Elliott, J. D.; Lago, M. A.; Cousins, R. D.; Gao, A.; Leber, J. D.; et al. 1,3-Diarylindan-2-carboxylic Acids, Potent and Selective Non-Peptide Endothelin Receptor Antagonists. J. Med. Chem. 1994, 37, 1553-1557.
51. Doherty, A. M.; Patt, W. C.; Edmunds, J. J.; Berryman, K. A.; Reisdorph, B. R.; et al. Discovery of a Novel Series of Orally Active Non-Peptide Endothelin-A Receptor-Selective Antagonists. J. Med. Chem. 1995, 38, 1259-1263.
52. Patt, W. C.; Edmunds, J. J.; Repine, J. P.; Berryman, K. A.; Reisdorph, B. R.; et al. Structure-Activity Relationship in a Series of Orally Active γ-Hydroxy Butenolide Endothelin Antagonists. J. Med. Chem. 1997, 40, 1063-1074.
53. Nishikibe, M.; Ohta, H.; Okade, M.; Ishikawa, K.; Hayama, T.; et al. Pharmacological Properties of J-104132 (L-753,037), a Potent, Orally Active, Mixed ETA/ETB Endothelin Receptor Antagonist. Am. Soc. Pharm. Exp. Ther. 1999, 283, 1262-1270.
54. Mederski, W. W.; Osswald, M.; Dorsch, D.; Christadler, M.; Schmitges, C. ; et al. Benzofuro[3,2-b]pyridines as Mixed ETA/ ETB and Selective ETB Endothelin Receptor Antagonists. Bioorg. Med. Chem. Lett. 1999, 9, 619-622.
55. Kukkola, P. J.; Bilci, N. A.; Ikler, T.; Savage, P.; Shetty, S. S.; et al. Isoindolines: A New Series of Potent and Seletive Endothelin-A Receptor Antagonists. Bioorg. Med. Chem. Lett. 2001, 11, 1737-1740.
56. Tasker, A. S.; Sorensen, B. K.; Jae, H.; Winn, M.; von Geldern, T. W.; et al. Potent and Selecitve Non-Benzodioxole-Containing Endothelin-A Receptor Antagonists. J. Med. Chem. 1997, 40, 322-330.
57. Derwent World Drug Index; Derwent Information Ltd.: London, 1996 (provided in Catalyst data format by Accelrys, Inc., 9685 Scranton Road, San Diego, CA 92121).
58. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and Computational Approaches To Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv. Drug. Dev. Rev. 1997, 23, 3-25.
59. Balakin, K. V.; Tkachenko, S. E.; Lang, S. A. O. I.; Ivashchenko, A. A.; Savchuk, N. P. Property-Based Design of GPCR-Targeted Library. J. Chem. Inf. Comput. Sci. 2002, 42, 1332-1342.
60. Ensemble: A New Database Affording a Unique, Integrated View of Drug Information; Prous Science: Barcelona, Spain, 2001; http://www.prous.com.
61. Maybridge Chemical Company. The Maybridge Database; Day-light Chemical Information Systems, Inc.: Mission Viejo, CA, 2001 (provided in Catalyst data format by Accelrys, Inc., 9685 Scranton Road, San Diego, CA 92121).
62. Webb, M. L.; Patel, P. S.; Rose, P. M.; Liu, E. C. K.; Stein, P. D.; et al. Mutational Analysis of the Endothelin Type A Receptor (ETA): Interactions and Model of the Selective ETA Antagonist BMS-182874 with the Putative ETA Receptor Binding Cavity. Biochemistry 1996, 35, 2548-2556.
63. Cramer, R. D., III; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
64. Tafi, A.; Costi, R.; Botta, M.; Di Santo, R.; Corelli, F.; et al. Antifungal Agents. 10. New Derivatives of 1-[(Aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, Synthesis, Anti-Candida Activity, and Quantitative Structure-Analysis Relationship Studies. J. Med. Chem. 2002, 45, 2720-2732
65. Patt, W. C.; Cheng, X. M.; Repine, J. T.; Lee, C.; Reisdorph, B. R.; et al. Butenolide Endothelin Antagonists with Improved Aqueous Solubility. J. Med. Chem. 1999, 42, 2162-2168
66. Liu, G.; Henry, K. J.; Szczepankiewicz, B. G.; Winn, M.; Kozmina, N. S.; et al. Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 3. Discovery of a Potent, 2-Nonaryl, Highly Selective ETA Antagonist (A-216546). J. Med. Chem. 1998, 41, 3261-3275.